CCL2 and type 2 diabetes mellitus: In a GK rat model of type 2 diabetes, treatment with IL-1 receptor antagonist (IL-1Ra) reduced islet mRNA expression of a number of inflammatory factors which includes: IL-1β, IL-6, TNF-α, MCP-1 and MIP-1α [58].